Profile data is unavailable for this security.
About the company
CNS Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system (CNS). The Company's lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is in development for the treatment of a number of serious brain and CNS oncology indications, including glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer. In addition, the Company is advancing the development of its WP1244/WP1874 drug technology, which utilizes anthracycline and distamycin-based scaffolds to create small molecule agents. The Company is also evaluating the use of WP1244/WP1874 in the treatment of other primary brain and central nervous system cancers, as well as cancers metastatic to the brain including pancreatic, ovarian, and lymphomas.
- Revenue in USD (TTM)0.00
- Net income in USD-15.97m
- Incorporated2017
- Employees3.00
- LocationCNS Pharmaceuticals Inc2100 West Loop S Ste 900HOUSTON 77027-3522United StatesUSA
- Websitehttps://cnspharma.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alaunos Therapeutics Inc | 7.00k | -19.13m | 4.52m | 1.00 | -- | 1.20 | -- | 645.08 | -11.95 | -11.95 | 0.0044 | 2.36 | 0.0004 | -- | 1.75 | 7,000.00 | -117.34 | -74.83 | -143.58 | -89.57 | -- | -- | -273,271.40 | -10,508.06 | -- | -- | 0.00 | -- | -99.83 | -49.08 | 6.86 | -- | -15.56 | -- |
| Palisade Bio Inc | 0.00 | -14.17m | 4.54m | 9.00 | -- | 0.3721 | -- | -- | -20.07 | -20.07 | 0.00 | 10.30 | 0.00 | -- | -- | 0.00 | -90.97 | -132.36 | -109.07 | -165.45 | -- | -- | -- | -27,892.32 | -- | -972.73 | 0.0339 | -- | -- | -0.7814 | 13.74 | -- | 18.53 | -- |
| ProtoKinetix, Inc. | 0.00 | -369.97k | 4.56m | 0.00 | -- | 11.25 | -- | -- | -0.0011 | -0.0011 | 0.00 | 0.0012 | 0.00 | -- | -- | -- | -78.67 | -696.88 | -85.20 | -785.51 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 78.22 | -- | 10.78 | -- |
| Azitra Inc | 408.20k | -9.96m | 4.57m | 10.00 | -- | 0.3332 | -- | 11.19 | -12.12 | -12.12 | 0.1151 | 1.80 | 0.0595 | -- | 1.83 | 40,820.00 | -145.30 | -- | -194.72 | -- | -- | -- | -2,440.46 | -- | -- | -- | 0.0191 | -- | 141.55 | -- | 6.02 | -- | -- | -- |
| Notable Labs Ltd | 313.00k | -16.74m | 4.62m | 16.00 | -- | 0.6425 | -- | 14.75 | -2.47 | -2.47 | 0.046 | 0.7439 | 0.0176 | -- | -- | 19,562.50 | -93.89 | -52.02 | -120.26 | -62.09 | 37.70 | 60.19 | -5,346.97 | -3,636.93 | -- | -- | 0.0405 | -- | -52.89 | -11.93 | 65.13 | -- | -50.69 | -- |
| Qualigen Therapeutics Inc | 0.00 | -9.27m | 4.80m | 4.00 | -- | -- | -- | -- | -1.66 | -1.75 | 0.00 | -0.445 | 0.00 | -- | -- | 0.00 | -134.64 | -- | -- | -- | -- | -- | -- | -- | -- | -9.64 | -- | -- | -- | -- | 10.22 | -- | -- | -- |
| CNS Pharmaceuticals Inc | 0.00 | -15.97m | 4.86m | 3.00 | -- | -- | -- | -- | -134.04 | -134.04 | 0.00 | -2.97 | 0.00 | -- | -- | 0.00 | -358.12 | -132.47 | -- | -185.75 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -23.42 | -- | -- | -- |
| Cingulate Inc | 0.00 | -19.10m | 4.89m | 13.00 | -- | 1.30 | -- | -- | -141.60 | -141.60 | 0.00 | 3.95 | 0.00 | -- | -- | 0.00 | -368.85 | -- | -- | -- | -- | -- | -- | -- | -- | -47.38 | 0.0042 | -- | -- | -- | -33.14 | -- | -- | -- |
| Pasithea Therapeutics Corp | 0.00 | -16.37m | 5.01m | 8.00 | -- | 0.3098 | -- | -- | -14.98 | -14.99 | 0.00 | 15.49 | 0.00 | -- | -- | 0.00 | -58.66 | -- | -62.74 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -32.23 | -- | -- | -- |
| Chromocell Therapeutics Corp | 0.00 | -8.98m | 5.02m | 4.00 | -- | 4.44 | -- | -- | -1.66 | -1.66 | 0.00 | 0.196 | 0.00 | -- | -- | 0.00 | -440.01 | -- | -- | -- | -- | -- | -- | -- | -- | -7.20 | 0.00 | -- | -- | -- | -200.20 | -- | -- | -- |
| Biostax Corp | 0.00 | -1.51m | 5.02m | -- | -- | -- | -- | -- | -0.0181 | -0.0181 | 0.00 | -0.0633 | 0.00 | -- | -- | -- | -395.44 | -81.51 | -- | -- | -- | -- | -- | -- | -- | -4.04 | -- | -- | -- | -- | 53.32 | -- | -- | -- |
| Oncternal Therapeutics Inc | 1.85m | -35.97m | 5.03m | 27.00 | -- | 0.3194 | -- | 2.73 | -12.19 | -12.19 | 0.6254 | 5.32 | 0.0495 | -- | -- | 68,370.37 | -96.40 | -49.40 | -116.52 | -54.51 | -- | -- | -1,948.70 | -1,342.98 | -- | -- | 0.00 | -- | -47.32 | -- | 10.62 | -- | -- | -- |
| Weed Inc | 0.00 | 57.30k | 5.05m | 2.00 | 80.17 | 671.36 | 58.38 | -- | 0.0005 | 0.0005 | 0.00 | 0.00006 | 0.00 | -- | -- | 0.00 | 6.00 | -385.93 | -- | -822.37 | -- | -- | -- | -- | -- | -46.08 | 0.944 | -- | -- | -- | 97.93 | -- | -59.13 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Anson Funds Management LPas of 30 Jun 2024 | 141.40k | 0.44% |
| UBS Securities LLCas of 30 Jun 2024 | 2.63k | 0.01% |
| Tower Research Capital LLCas of 30 Jun 2024 | 115.00 | 0.00% |
| Wells Fargo Advisors Financial Network LLCas of 30 Jun 2024 | 4.00 | 0.00% |
| Global Retirement Partners LLCas of 30 Jun 2024 | 2.00 | 0.00% |
| Morgan Stanley Smith Barney LLC (Investment Management)as of 30 Jun 2024 | 2.00 | 0.00% |
| Parallel Advisors LLCas of 30 Jun 2024 | 1.00 | 0.00% |
| Plante Moran Financial Advisors LLCas of 30 Jun 2024 | 1.00 | 0.00% |
| Bank of America, NA (Private Banking)as of 30 Jun 2024 | 1.00 | 0.00% |
| Strategic Advisers LLCas of 30 Jun 2024 | 1.00 | 0.00% |
